Indication intelligence, analysis and sector perception

Capricor Therapeutics (CAPR) NIH grant of $4.2 M to Evaluate Exosomes for Hypoplastic Left Heart Syndrome

October 20, 2016 9:07am

Non-dilutive capital, CAPR had closed at $3.44 - BUY

CAPR has been awarded a grant of up to $4.2 M from the National Institutes of Health to study CAP-2003 (cardiosphere-derived cell exosomes) for hypoplastic left heart syndrome (HLHS).

CAP-2003 represents exosomes isolated from CAPR's allogeneic cardiosphere-derived cells, (CAP-1002), which are in clinical development for several cardiac conditions including that associated with Duchenne muscular dystrophy.

CAP-2003 has shown compelling data in models of eye injury, and CAPR hopes to initiate a clinic trial next year for ocular graft-versus-host disease, a condition involving severe dry eye, pain and light sensitivity that is a frequent complication of bone marrow transplant.

The Bottom Line: non-dilutive sources of capital reinforces balance sheet as well as technology platform; to date, CAPR have been awarded over $30 M from government agencies to support the preclinical and clinical advancement of our cell and exosome candidates. This is the second federally-funded application that broadens the scope of its exosome program.

Exosomes offer a different approach to regenerative medicine as compared to cell-based strategies, and can be handled more like traditional pharmaceuticals. CAP-2003 is independent of its cells of origin. This product may offer opportunities for clinical use that may not be ideal targets for a cellular therapeutic product (CAP-1002, allogeneic cardiosphere-derived cells).

CAPR had closed DOWN -$0.01 to $3.44 - BUY

HLHS is a tragic congenital defect of the heart that often results in heart failure and premature death despite several complex surgeries.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

52 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.